Press Releases

 
Press Releases
  Date Title and Summary View
Dec 4, 2016
ARQ 531 demonstrates best-in-class potential as a reversible, non-covalent BTK inhibitor BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data was presented on Bruton's tyrosine kinase (BTK) inhibitor, ARQ 531, in a poster presentatio...
Dec 3, 2016
The study supports further exploration of ARQ 092 in sickle cell disease BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data was presented on its proprietary AKT inhibitor, ARQ 092, in an oral presentation by the University of Illin...
Nov 7, 2016
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2016. For the quarter ended September 30, 2016, the Company reported a net loss of...
Nov 3, 2016
BTK inhibitor, ARQ 531, potently inhibits wild type and C481S mutant BTK and is superior to ibrutinib in TCL1 mouse model for CLLAKT inhibitor, ARQ 092, has potential to treat Sickle Cell Disease BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today ...
Oct 24, 2016
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2016 before the market opens on Monday, November 7, 2016. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results an...
Sep 21, 2016
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at The Leerink Partners Rare Disease and Immuno-Oncology Roundtable on September 28th, ...
Sep 15, 2016
PLOS ONE publication supports phase 1/2 intrahepatic cholangiocarcinoma trial with ARQ 087 in patients with FGFR2 genetic alterations BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced the publication of a paper detailing the preclinical profile of ARQ ...
Aug 3, 2016
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2016. For the quarter ended June 30, 2016, the Company reported a net loss of ...
Jul 20, 2016
BURLINGTON, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the second quarter 2016 before the market opens on Wednesday, August 3, 2016.  The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general busin...
Jul 18, 2016
Data supports further preclinical and clinical research in BTK sensitive and ibrutinib resistant malignancies BURLINGTON, Mass., July 18, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced the first public presentation of data on its novel BTK inhibitor, ARQ 531, at the 2016 Pan Pacific Lymphoma Conference in Koloa, Hawaii. ...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300